IPG-LETROZOLE TABLET
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
24-03-2020
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
LETROZOLE
から入手可能:
MARCAN PHARMACEUTICALS INC
ATCコード:
L02BG04
INN（国際名）:
LETROZOLE
投薬量:
2.5MG
医薬品形態:
TABLET
構図:
LETROZOLE 2.5MG
投与経路:
ORAL
パッケージ内のユニット:
30/100
処方タイプ:
Prescription
治療領域:
ANTINEOPLASTIC AGENTS
製品概要:
Active ingredient group (AIG) number: 0132937001; AHFS:
認証ステータス:
APPROVED
承認日:
2016-06-24
製品の特徴
Page 1 of 63
PRODUCT MONOGRAPH
PR
IPG-LETROZOLE
Letrozole Tablets, USP
2.5 mg Tablets
Non-steroidal aromatase inhibitor;
inhibitor of estrogen biosynthesis;
anti-tumour agent
Marcan Pharmaceuticals Inc.
2 Gurdwara Road, Suite # 112
Date of Revision:
March 24, 2020
Ottawa, ON K2E 1A2
CONTROL # 237051
Page 2 of 63
CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................................................3
SUMMARY PRODUCT INFORMATION
...........................................................................................................3
INDICATIONS AND CLINICAL USE
.................................................................................................................3
CONTRAINDICATIONS
......................................................................................................................................4
WARNINGS AND PRECAUTIONS
....................................................................................................................4
ADVERSE REACTIONS
......................................................................................................................................9
DRUG INTERACTIONS
....................................................................................................................................
25
DOSAGE AND ADMINISTRATION
................................................................................................................
27
OVERDOSAGE
..................................................................................................................................................
28
ACTION AND CLINICAL PHARMACOLOGY
..............................................................................................
28
STORAGE AND STABILITY
...........................................................................................................................
30
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................................................
30
P
完全なドキュメントを読む
